209 related articles for article (PubMed ID: 23891738)
1. Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells.
Liu D; Song L; Brawley VS; Robison N; Wei J; Gao X; Tian G; Margol A; Ahmed N; Asgharzadeh S; Metelitsa LS
Clin Immunol; 2013 Oct; 149(1):55-64. PubMed ID: 23891738
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas.
Teo WY; Elghetany MT; Shen J; Man TK; Li X; Chintagumpala M; Su JM; Dauser R; Whitehead W; Adesina AM; Lau CC
J Neurooncol; 2014 Nov; 120(2):293-301. PubMed ID: 25115738
[TBL] [Abstract][Full Text] [Related]
3. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.
Metelitsa LS
Clin Immunol; 2011 Aug; 140(2):119-29. PubMed ID: 21095162
[TBL] [Abstract][Full Text] [Related]
5. Defining a novel subset of CD1d-dependent type II natural killer T cells using natural killer cell-associated markers.
Singh AK; Rhost S; Löfbom L; Cardell SL
Scand J Immunol; 2019 Sep; 90(3):e12794. PubMed ID: 31141185
[TBL] [Abstract][Full Text] [Related]
6. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.
Song L; Asgharzadeh S; Salo J; Engell K; Wu HW; Sposto R; Ara T; Silverman AM; DeClerck YA; Seeger RC; Metelitsa LS
J Clin Invest; 2009 Jun; 119(6):1524-36. PubMed ID: 19411762
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms.
Bagnara D; Ibatici A; Corselli M; Sessarego N; Tenca C; De Santanna A; Mazzarello A; Daga A; Corvò R; De Rossi G; Frassoni F; Ciccone E; Fais F
Haematologica; 2009 Jul; 94(7):967-74. PubMed ID: 19454494
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
Webb TJ; Bieler JG; Schneck JP; Oelke M
J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
[TBL] [Abstract][Full Text] [Related]
9. The Role of Adaptor Proteins in the Biology of Natural Killer T (NKT) Cells.
Gerth E; Mattner J
Front Immunol; 2019; 10():1449. PubMed ID: 31293596
[TBL] [Abstract][Full Text] [Related]
10. Complementary approaches to study NKT cells in cancer.
Berzofsky JA; Olkhanud PB; Terabe M
Methods Enzymol; 2020; 631():371-389. PubMed ID: 31948558
[TBL] [Abstract][Full Text] [Related]
11. Bcl-xL regulates CD1d-mediated antigen presentation to NKT cells by altering CD1d trafficking through the endocytic pathway.
Subrahmanyam PB; Carey GB; Webb TJ
J Immunol; 2014 Sep; 193(5):2096-105. PubMed ID: 25070854
[TBL] [Abstract][Full Text] [Related]
12. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.
Tian G; Courtney AN; Jena B; Heczey A; Liu D; Marinova E; Guo L; Xu X; Torikai H; Mo Q; Dotti G; Cooper LJ; Metelitsa LS
J Clin Invest; 2016 Jun; 126(6):2341-55. PubMed ID: 27183388
[TBL] [Abstract][Full Text] [Related]
13. Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells.
East JE; Sun W; Webb TJ
J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299308
[TBL] [Abstract][Full Text] [Related]
14. Targeted disruption of CD1d prevents NKT cell development in pigs.
Yang G; Artiaga BL; Hackmann TJ; Samuel MS; Walters EM; Salek-Ardakani S; Driver JP
Mamm Genome; 2015 Jun; 26(5-6):264-70. PubMed ID: 25930071
[TBL] [Abstract][Full Text] [Related]
15. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
Kronenberg M
J Vis Exp; 2007; (10):635. PubMed ID: 18989407
[TBL] [Abstract][Full Text] [Related]
16. A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer.
Seki T; Liu J; Brutkiewicz RR; Tsuji M
Anticancer Res; 2019 Feb; 39(2):549-555. PubMed ID: 30711929
[TBL] [Abstract][Full Text] [Related]
17. CD1d activation and blockade: a new antitumor strategy.
Teng MW; Yue S; Sharkey J; Exley MA; Smyth MJ
J Immunol; 2009 Mar; 182(6):3366-71. PubMed ID: 19265113
[TBL] [Abstract][Full Text] [Related]
18. CD1d-Restricted Type II NKT Cells Reactive With Endogenous Hydrophobic Peptides.
Nishioka Y; Masuda S; Tomaru U; Ishizu A
Front Immunol; 2018; 9():548. PubMed ID: 29599785
[TBL] [Abstract][Full Text] [Related]
19. Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset.
Dasgupta S; Kumar V
Immunogenetics; 2016 Aug; 68(8):665-76. PubMed ID: 27405300
[TBL] [Abstract][Full Text] [Related]
20. CD1d-dependent NKT cells play a protective role in acute and chronic arthritis models by ameliorating antigen-specific Th1 responses.
Teige A; Bockermann R; Hasan M; Olofsson KE; Liu Y; Issazadeh-Navikas S
J Immunol; 2010 Jul; 185(1):345-56. PubMed ID: 20525883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
